Sep 2026· Journal of Experimental Medicine· Vol 223· 0 citations
Medicine
TL;DR
This work identifies CaM kinase-like vesicle-associated protein (CAMKV) as a MYCN/MYC-regulated effector of NB pathogenesis and establishes CAMKV as a central signaling hub that coordinates metabolic and proliferative pathways.
Abstract
High-risk (HR) neuroblastoma (NB) remains a leading cause of pediatric cancer mortality, frequently driven by MYCN amplification or MYC overexpression. Despite their central role, direct pharmacological targeting of these transcription factors remains clinically challenging. Here, we identify CaM kinase-like vesicle-associated protein (CAMKV) as a MYCN/MYC-regulated effector of NB pathogenesis. Although previously classified as a non-functional pseudokinase, we demonstrate that CAMKV possesses intrinsic kinase activity that is essential for tumor growth. Analysis of patient datasets and primary tumors shows that elevated CAMKV expression correlates with advanced disease stage and poor overall survival. Through integrated transcriptomics, ChIP-seq, and phosphoproteomics, we establish CAMKV as a central signaling hub that coordinates metabolic and proliferative pathways. Both genetic depletion and small-molecule inhibition of CAMKV significantly impair NB cell proliferation in vitro and suppress tumor growth in vivo. Collectively, our findings establish CAMKV as a unifying therapeutic vulnerability and highlight this functional kinase as a promising target for translational development in HR NB.
Background Myosin light chain 9 (MYL9), a regulatory light chain of myosin II, plays a crucial role in cytoskeletal dynamics and has been associated with tumor progression in multiple malignancies. However, its role in lung adenocarcinoma (LUAD) remains poorly characterized. Despite recent advances in treatment, the pr...
Xiang Tan, Ye Chen, Min-Lian Nong et al.· Journal of Thoracic Disease· 0 citations
A key strategy for precision therapy lies in identifying and targeting tumor cell-specific metabolic vulnerabilities to develop effective combination treatments. In this study, we demonstrate that vandetanib, a multi-kinase inhibitor, acts as a potent transcriptional repressor of the serine synthesis pathway (SSP) in...
Yan Zhou, Yin-Yin Xie, Fu-Hui Wang et al.· Cell Death & Disease· 0 citations
Acute myeloid leukemia (AML) represents a critical focus for biomarker research, given its high mortality, rapid progression, substantial treatment resistance, and marked genetic heterogeneity. The present study identifies PTP4A3 as a relevant molecular determinant in the disease, linking its overexpression to advers...
Natália Sudan Parducci, Maria Fernanda Lopes Carvalho, I. C. Santos et al.· ACS Pharmacology & Trans...· 0 citations
Receptor-interacting protein kinase 1 (RIPK1) plays a pivotal role in regulating cell survival and death, thereby exerting complex and multifaceted functions in the initiation and progression of cancer. Its expression is frequently dysregulated across diverse malignancies and correlates strongly with poor prognosis, hi...
Jing-Yu Luo, Shu-Ya Song, Ze-Kun Li et al.· Cellular Signalling· 0 citations
SHP2 is a tyrosine phosphatase that mediates intracellular signaling downstream of transmembrane receptors regulated by a pair of src homology 2 (SH2) domains. Its overexpression and mutation are pivotal in driving tumor progression by influencing various cancer's fundamental characteristics, such as metastasis, DNA re...
Maryam Jama, M. Overduin, K. Barakat· Medicinal research reviews (...· 0 citations
Glioblastoma (GBM) remains a highly aggressive brain tumor with limited therapeutic options, highlighting the need to identify novel tumor vulnerabilities. Citron kinase (CITK), a protein involved in cytokinesis and genome stability, is required for the proliferation and survival of neural progenitors and has previousl...
Alessia Ferraro, L. Lazzerini, Giorgia Iegiani et al.· International Journal of Mol...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.